<DOC>
	<DOCNO>NCT01816243</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Transdermal Therapeutic System ( TTS ) -fentanyl patch ( transdermal patch contain drug put skin drug enter body skin ) Thai participant chronic ( last long time ) non-malignant ( non-cancerous ) pain .</brief_summary>
	<brief_title>An Efficacy Safety Study Transdermal Therapeutic System ( TTS ) -Fentanyl Thai Participants With Chronic Non-Malignant Pain</brief_title>
	<detailed_description>This open label ( people know identity intervention ) , single arm study ass efficacy safety TTS-fentanyl Thai participant chronic non-malignant pain ( except headache central spinal cord mediate pain ) . The study consist 2 phase : stabilization phase ( 7 day start treatment ) treatment phase ( 30 day ) . The first patch apply Investigator participant 30 day . All participant start treatment patch release 25 microgram per hour ( mcg/h ) fentanyl . The patch replace every 3 day . On Day 3 , every 3 day thereafter , TTS-fentanyl dose titrate ( slow increase drug dosage , guide participant 's response ) per participant 's need . The duration treatment 30 day first patch application . The dose TTS-fentanyl slowly increase need , 25 mcg/h achieve adequate pain control . No increase TTS-fentanyl dose perform within 72-hour dose interval . Participants allow use oral morphine syrup duration TTS-fentanyl treatment enable appropriate TTS-fentanyl dose titration . Primary efficacy assessment pain control rat participant . Assessment time point Day 0 ( Baseline ) , Day 15 Day 30 ( trial end ) . At end study , global preference efficacy , side effect overall satisfaction also rat Investigator participant . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Participants chronic nonmalignant pain ( etiology except headache central spinal cord mediate pain ) moderate ( medium level seriousness ) severe ( serious , life threaten ) pain require treatment potent opioid Participants must also currently treat short long act opioid medication Transdermal Therapeutic System ( TTS ) fentanyl dose less equal 134 milligram per day ( mg/day ) oral morphine ( equianalgesic dose another opioid ) , participant may treat TTSfentanyl past Participants side effect receive Non Steroidal Antiinflammatory Drugs ( NSAIDs ) Participants fail treatment operation lack efficacy current treatment Participants spinal cord stimulators may enroll , provide turn spinal cord stimulator duration trial , leave continually duration trial History allergy , hypersensitivity , lack ability tolerate fentanyl Skin disease precludes use transdermal system could affect absorption fentanyl local tolerability History suspicion alcohol drug abuse within past 5 year History narcotic ( strong habitforming drug stop pain depresses central nervous system ) therapy Pregnancy breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Pain</keyword>
	<keyword>Chronic Non-Malignant Pain</keyword>
	<keyword>TTS-fentanyl</keyword>
	<keyword>Durogesic</keyword>
</DOC>